Gastroenterology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Gastroenterology Search

Gastroenterology

Gastroenterology

Home News Diseases Conferences Special Reports

Microwave ablation: A better minimally invasive technique for HCC?

Audrey Abella, Yesterday

A systematic review and meta-analysis evaluating two percutaneous ablation techniques – microwave ablation (MWA) and radiofrequency ablation (RFA) – showed that the former fared better than the latter in reducing local tumour progression (LTP) rates in individuals with hepatocellular carcinoma (HCC) and/or liver metastases.

Oral antibiotics noninferior to IV antibiotics for K. pneumoniae liver abscess

Roshini Claire Anthony, 5 days ago

Adults hospitalized for liver abscess due to Klebsiella pneumoniae (K. pneumoniae) could be treated with oral rather than intravenous (IV) antibiotics, according to a trial from Singapore.

Medication nonadherence may lead to treatment escalation in children with UC

03 Nov 2019

In paediatric patients with ulcerative colitis (UC), nonadherence to mesalazine negatively affects its therapeutic efficacy and may, in turn, result in treatment escalation, according to data from PROTECT.

Long‐term biological therapy likely needed in perianal Crohn’s disease management

01 Nov 2019

Discontinuation of antitumour necrosis factor (anti-TNF) therapy for perianal Crohn’s disease is highly likely to lead to relapse, with some patients even requiring defunctioning surgery, according to a study conducted across Asia.

Antitumour necrosis factor alpha therapy reduces colectomy, corticosteroid use

31 Oct 2019

Treatment with the antitumour necrosis factor alpha appears to be beneficial in paediatric and adolescent patients with ulcerative colitis (UC), leading to lower colectomy rates within a period of 5 years and termination of corticosteroid use after 12 months, as shown in a recent study.

PyloBalance as an adjunct therapy in the treatment of H. pylori infections

17 Jul 2019

All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2

MIMS Gasteroenterology Supplement June 2018

19 Jun 2018

There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.

Optimizing the management of Helicobacter pylori infection

04 Jan 2017

Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.

The role of direct-acting antivirals in the new era of hepatitis C treatment

14 Dec 2016

At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.

Child-Pugh score a prognostic factor for sorafenib response in HCC patients?

Jairia Dela Cruz, 06 Dec 2016

Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.

TAS-118 + oxaliplatin outdoes S-1 + cisplatin in improving survival in advanced gastric cancer

Roshini Claire Anthony, 15 Jul 2019

The combination of TAS-118 and oxaliplatin led to significantly greater survival compared with the S-1 and cisplatin combination in patients with metastatic or recurrent HER2-negative gastric cancer, the phase III SOLAR* study showed.

Dose reduction has little impact on regorafenib tolerability, efficacy not compromised

Roshini Claire Anthony, 12 Jul 2019

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.

Ramucirumab ups survival in advanced HCC regardless of prior TACE

Pearl Toh, 11 Jul 2019

The survival benefit with ramucirumab was consistent in patients with advanced hepatocellular carcinoma (HCC) and high alpha-fetoprotein (AFP) levels regardless of whether they were previously treated with transarterial chemoembolization (TACE), a post hoc analysis of pooled data from the REACH/REACH-2 studies shows.

Add-on bevacizumab improves efficacy of trifluridine/tipiracil in mCRC

Elaine Soliven, 11 Jul 2019

Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.

Triplet-targeted therapy a BEACON of hope for patients with BRAF-V600E mCRC

Pearl Toh, 09 Jul 2019

A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).

Encouraging efficacy with glecaprevir-pibrentasvir combo in HCV

Roshini Claire Anthony, 10 May 2019

Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.

Rising risk of NAFLD-related mortality in HIV+ individuals

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!